File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide

TitleInduction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide
Authors
Issue Date1990
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy And Pharmacology, 1990, v. 26 n. 5, p. 380-382 How to Cite?
AbstractA total of 46 patients with previously untreated acute myeloid leukaemia were treated with an induction regimen consisting of 100 mg/m 2 cytosine arabinoside fiven daily by 18-h i.v. infusion for 7 days, 50 mg/m 2 daunorubicin given daily by i.v. bolus injection for 3 days and 75 mg/m 2 etoposide given daily by 1-h i.v. infusion for 7 days. In all, 30 patients (67%) went into complete remission and were given further consolidation and maintenance chemotherapy. Of the 31 complete responders, 15 (48%) relapsed. The median disease-free survival of the 31 complete responders and the median overall survival of all 46 patients were 25 and 14 months, respectively. None of the clinical characteristics, which included sex, age, FAB morphology, extramedullary disease and initial WBC count, predicted the clinical response. Myelosuppression was the major toxicity and non-haematological side effects were acceptable. The regimen appeared to have acceptable toxicity, and its efficacy was comparable with that of standard regimens.
Persistent Identifierhttp://hdl.handle.net/10722/161819
ISSN
2015 Impact Factor: 2.824
2015 SCImago Journal Rankings: 1.283
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_US
dc.contributor.authorChiu, Een_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorTodd, Den_US
dc.date.accessioned2012-09-05T05:15:16Z-
dc.date.available2012-09-05T05:15:16Z-
dc.date.issued1990en_US
dc.identifier.citationCancer Chemotherapy And Pharmacology, 1990, v. 26 n. 5, p. 380-382en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttp://hdl.handle.net/10722/161819-
dc.description.abstractA total of 46 patients with previously untreated acute myeloid leukaemia were treated with an induction regimen consisting of 100 mg/m 2 cytosine arabinoside fiven daily by 18-h i.v. infusion for 7 days, 50 mg/m 2 daunorubicin given daily by i.v. bolus injection for 3 days and 75 mg/m 2 etoposide given daily by 1-h i.v. infusion for 7 days. In all, 30 patients (67%) went into complete remission and were given further consolidation and maintenance chemotherapy. Of the 31 complete responders, 15 (48%) relapsed. The median disease-free survival of the 31 complete responders and the median overall survival of all 46 patients were 25 and 14 months, respectively. None of the clinical characteristics, which included sex, age, FAB morphology, extramedullary disease and initial WBC count, predicted the clinical response. Myelosuppression was the major toxicity and non-haematological side effects were acceptable. The regimen appeared to have acceptable toxicity, and its efficacy was comparable with that of standard regimens.en_US
dc.languageengen_US
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshChi-Square Distributionen_US
dc.subject.meshCytarabine - Administration & Dosageen_US
dc.subject.meshDaunorubicin - Administration & Dosageen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshDrug Evaluationen_US
dc.subject.meshEtoposide - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, Myeloid, Acute - Drug Therapy - Mortalityen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshSurvival Rateen_US
dc.titleInduction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposideen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/BF02897299-
dc.identifier.pmid2208581en_US
dc.identifier.scopuseid_2-s2.0-0025025767en_US
dc.identifier.volume26en_US
dc.identifier.issue5en_US
dc.identifier.spage380en_US
dc.identifier.epage382en_US
dc.identifier.isiWOS:A1990DX84800016-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridChiu, E=24827833600en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats